SynthesisInternational wound journal2026
Cellular, Acellular, and Matrix-Like Placental Products for Diabetic Foot Ulcers: A 12-Week Randomised-Trial Meta-Analysis.
Synthesis in International wound journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Placental-derived cellular, acellular, and matrix-like products (CAMPs) are widely used as adjuncts to standard care for diabetic foot ulcers (DFUs), but trials differ in product class, comparator, and healing window. We estimated the effect of adjunctive placental-derived CAMPs on complete wound closure at a single, clinically meaningful 12-week endpoint. The review was registered in the International Prospective Register of Systematic Reviews (PROSPERO; CRD420261399700) and reported per Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020, with search reporting guided by PRISMA-S. PubMed/MEDLINE, Scopus, and the Cochrane Central Register of Controlled Trials (CENTRAL) were searched through 21 June 2026 for randomised or quasi-randomised trials comparing a placental, amniotic, chorionic, amnion-chorion, placental membrane, or umbilical cord-derived product plus standard care against standard care or a non-placental control in adults with active DFUs. The primary outcome was complete wound closure at 12 weeks. Risk ratios (RRs) were pooled in a random-effects model (inverse-variance, restricted maximum likelihood [REML], Hartung-Knapp). Risk of bias was assessed with the Cochrane Risk of Bias 2 tool (RoB 2) for the 12-week outcome and certainty with the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach. Prespecified sensitivity analyses included odds ratios, leave-one-out, product-class subgroups, and exclusion of high-risk-of-bias studies. Of 474 records, 14 randomised articles were retained; 9 standard-care-controlled comparisons (944 participants) provided extractable 12-week complete-closure data for the primary analysis. Complete closure occurred in 298 of 505 product-treated participants (59.0%) versus 157 of 439 controls (35.8%). Adjunctive CAMPs increased the likelihood of closure (RR 1.70, 95% confidence interval [CI] 1.31-2.20). Heterogeneity was moderate (I
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.